Beginning July 1, 2026, Medicare beneficiaries will have access to a new pilot program, the Medicare GLP-1 Bridge, which allows coverage for GLP-1 medications prescribed for weight loss at a copayment of $50 per month. This initiative marks a significant change for Medicare, which has historically excluded weight loss treatments from coverage. The program will run until December 31, 2027, and aims to provide a temporary solution before a potential long-term coverage plan is evaluated for 2028.
The GLP-1 medications included in this program are Wegovy, Zepbound, and Foundayo, available in both injectable and pill forms. Current cash prices for these drugs can range from $149 to $699 monthly, making them unaffordable for many. According to KFF polling, nearly half of GLP-1 users report difficulty affording these medications, highlighting the importance of this new coverage option. Eligibility for the program requires enrollment in a Medicare Part D plan and is primarily based on body mass index (BMI) and associated health conditions.
While the $50 copayment offers a more predictable cost for patients, it does not contribute to the Part D deductible or the annual out-of-pocket cap, which could pose challenges for low-income beneficiaries. Additionally, those receiving low-income subsidies cannot apply this assistance to the GLP-1 Bridge program. The program's structure requires prior authorization from healthcare providers, which may complicate access for some patients.
As the pilot program approaches its end date in December 2027, the future of GLP-1 coverage in Medicare remains uncertain. The initial plan for a longer-term program faced challenges, including insufficient insurer participation. Stakeholders will need to monitor the outcomes of this pilot to inform future decisions regarding obesity treatment coverage in Medicare.
KFF Health News · May 6The White House has released its National Drug Control Strategy, a comprehensive 195-page document aimed at addressing the ongoing drug addiction crisis in the United States. The strategy outlines ambitious goals such as improving access to treatment, preventing youth addiction, supporting recovery, and reducing overdose deaths. These objectives have garnered support from public health experts and addiction advocates. However, many are concerned that the administration's recent actions, including significant cuts to federal funding and Medicaid, may undermine these efforts.
Since 2000, over 1.1 million Americans have died from drug overdoses, with recent data indicating that overdose death rates remain disproportionately high among Black and Native American populations. The strategy emphasizes law enforcement measures to combat drug supply, including increased border enforcement and the use of artificial intelligence for drug screening. It also promotes public health initiatives aimed at reducing drug demand, such as expanding access to overdose reversal medications like naloxone.
Despite the strategy's positive intentions, experts highlight a disconnect between the proposed goals and the funding realities. The administration's budget proposals threaten to cut vital addiction and mental health programs, raising concerns about the stability of treatment services. Additionally, the implementation of Medicaid work requirements could strip coverage from approximately 1.6 million individuals with substance use disorders, further complicating access to necessary care.
As the administration moves forward with its strategy, stakeholders in the addiction treatment field are calling for Congress to reject proposed budget cuts and ensure that funding aligns with the stated goals of improving treatment access and supporting recovery efforts. The success of the National Drug Control Strategy will depend on the administration's ability to reconcile its public health ambitions with its fiscal policies.
KFF Health News · May 6Martin Luther King, Jr. Community Hospital in Los Angeles is experiencing severe financial strain, with emergency department patients waiting on gurneys and overflow mental health patients placed in outdoor tents. The 152-bed facility serves a predominantly low-income community, with 75% of its revenue derived from Medi-Cal, California's Medicaid program, which pays lower rates compared to other hospitals. The situation is exacerbated by the One Big Beautiful Bill Act, signed into law by President Trump, which is projected to cut federal Medicaid spending by $911 billion over the next decade, potentially increasing the uninsured population by over 14 million.
In response to these challenges, state lawmakers are exploring financial assistance options. California Assembly member Esmeralda Soria is advocating for an expansion of a distressed hospital loan fund that previously allocated nearly $300 million in zero-interest loans to 16 hospitals, including $14 million to MLK. Other states, such as Pennsylvania and Illinois, are also considering similar funding initiatives to support struggling hospitals.
Despite these efforts, the financial outlook remains grim. MLK's leadership anticipates an annual revenue shortfall of $80 million to $100 million, the largest since the hospital's opening in 2015. The California Hospital Association has expressed concerns that existing support is insufficient, as many hospitals continue to face financial instability. As state budgets tighten, the future of these funding initiatives remains uncertain, with potential cuts looming in the upcoming fiscal year.
Healthcare advocates emphasize the need for immediate action to prevent further deterioration of hospital services, particularly in underserved communities. The situation highlights the critical intersection of healthcare funding, policy decisions, and the well-being of vulnerable populations across the nation.
KFF Health News · May 5